All News
Filter News
Found 167 articles
-
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
9/22/2021
Equillium, Inc today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference, taking place September 27 – 30, 2021.
-
Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/8/2021
Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Acute Graft Versus Host Disease [GvHD] Treatment Market: Intravenous Segment to Expand at High Growth Rate
8/23/2021
According to the report, the global acute graft versus host disease treatment market was valued at US$ 263 Mn in 2020 and is projected to expand at a CAGR of 8.6% from 2021 to 2031.
-
Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
8/11/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced additional data from the EQUALISE Type A portion of the study in systemic lupus erythematosus (SLE) patients.
-
Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update
8/10/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2021, and provided an update on its clinical programs.
-
Equillium to Present at the BTIG Virtual Biotechnology Conference
8/5/2021
Equillium, Inc. announced today that it will present at the BTIG Virtual Biotechnology Conference, taking place August 9 & 10, 2021.
-
Clinical Catch-Up: July 12-16
7/19/2021
It was a moderately busy mid-summer week for clinical trial news. Here’s a look. -
Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA
7/12/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the completion of an End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD)
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
-
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
6/11/2021
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced positive topline data from the Phase 1b EQUATE study in first-line acute graft-versus-host-disease.
-
Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry
6/10/2021
Equillium, Inc. announced a poster presented yesterday at the CYTO Virtual Interactive Meeting, highlighting a novel assay to measure target engagement and modulation of CD6 as a pharmacodynamic marker for effect on T cells following treatment with itolizumab.
-
Equillium to Present at the JMP Securities Life Sciences Conference
6/9/2021
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.
-
Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases
6/7/2021
Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a translational research collaboration with the Kennedy Institute for Rheumatology and the Sir William Dunn School of Pathology, University of Oxford.
-
Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11
6/3/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will host a conference call on Friday, June 11, 2021, at 8:00 am ET,
-
Equillium to Present at the Jefferies Virtual Healthcare Conference
5/26/2021
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that it will present at the Jefferies Virtual Healthcare Conference taking place June 1 – 4, 2021.
-
Equillium Presents Multiple Posters at the 104th Annual Meeting of the American Association of Immunologists
5/17/2021
Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that three posters detailing the novel mechanistic activity of itolizumab were presented at the 2021 American Association of Immunologists (AAI) Annual Meeting held May 10-15, 2021
-
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
5/13/2021
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that an abstract highlighting positive data from the EQUATE study of itolizumab in acute graft-versus-host disease has been accepted for oral presentation at EHA2021 Virtual Congress.
-
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update
5/13/2021
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced financial results for the first quarter 2021, and provided an update on its clinical development programs.
-
Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists
4/27/2021
Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients